The newest class of Alzheimer’s disease medications is the first to show that it can slow the disease itself. These treatments typically allow patients to remain independent for about 10 additional months. Known as monoclonal antibodies, the…
Continue Reading
News Source: www.sciencedaily.com
Leave a Reply